Nephros Inc. (NASDAQ:NEPH) Stock Short Interest Report for September

Nephros Inc. (NASDAQ:NEPH) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 25,302 shares, a decrease of 45.5% from the September 15th total of 46,400 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 18,272 shares, the short-interest ratio is currently 1.4 days.

Institutional Investors Weigh In On Nephros

Institutional investors and hedge funds have recently made changes to their positions in the business. De Lisle Partners LLP acquired a new stake in Nephros during the second quarter worth approximately $62,000. BlackRock Inc. acquired a new position in Nephros in the second quarter valued at approximately $67,000. Dimensional Fund Advisors LP lifted its stake in Nephros by 52.5% in the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after buying an additional 7,144 shares during the period. Navellier & Associates Inc. boosted its holdings in shares of Nephros by 179.6% during the 2nd quarter. Navellier & Associates Inc. now owns 53,479 shares of the company’s stock worth $191,000 after buying an additional 34,353 shares in the last quarter. Finally, Bard Associates Inc. bought a new position in shares of Nephros during the 2nd quarter worth approximately $421,000. Institutional investors own 41.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NEPH. Northland Securities began coverage on Nephros in a report on Friday, July 17th. They set a “market perform” rating and a $4.00 target price on the stock. Zacks Research raised Nephros to a “hold” rating in a research note on Monday, July 20th. Benchmark reissued a “speculative buy” rating on shares of Nephros in a research note on Tuesday, August 18th. Finally, Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nephros Stock Performance

Shares of NASDAQ:NEPH traded up $0.14 during trading on Friday, reaching $3.65. The stock had a trading volume of 45,997 shares, compared to its average volume of 32,517. The firm’s fifty day moving average is $4.11 and its 200 day moving average is $3.60. Nephros has a 52 week low of $2.66 and a 52 week high of $6.42. The stock has a market cap of $39.64 million, a price-to-earnings ratio of 22.81 and a beta of 1.64.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter. The business had revenue of $6.02 million during the quarter, compared to the consensus estimate of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 10.60%. On average, research analysts forecast that Nephros will post 0.15 earnings per share for the current fiscal year.

About Nephros

Nephros, Inc is a medical device company that develops and sells filtration products for healthcare and commercial applications. Its primary focus is point-of-use water filtration systems designed to help reduce bacteria, including waterborne pathogens such as Legionella, in hospitals, long-term care facilities, and other healthcare settings.

The company’s product portfolio includes disposable and durable water filtration systems intended for use at sinks, showers, and other water outlets.